Market Place
Sourcing Support
89bio Announces Inducement Grants Under Nasdaq LR 5635(c)(4)
19 Dec 2024 //
GLOBENEWSWIRE
89bio Announces Inducement Grants Under Nasdaq LR 5635(c)(4)
29 Nov 2024 //
GLOBENEWSWIRE
89bio to Participate in 7th Annual Evercore HealthCONx Conference
26 Nov 2024 //
GLOBENEWSWIRE
89bio Presents Pegozafermin Data, Non-Invasive Test in MASH
15 Nov 2024 //
GLOBENEWSWIRE
89bio Announces Proposed Public Offering of Common Stock
12 Nov 2024 //
GLOBENEWSWIRE
89bio Announces Upsized Pricing of $125.0 Million Public Offering
12 Nov 2024 //
GLOBENEWSWIRE
89bio Reports Q3 2024 Financial Results & Corporate Updates
07 Nov 2024 //
GLOBENEWSWIRE
89bio to Participate in UBS Global Healthcare Conference
05 Nov 2024 //
GLOBENEWSWIRE
89bio Presents New Analyses From Enliven Phase 2b Trial for MASH
15 Oct 2024 //
GLOBENEWSWIRE
89bio Announces Inducement Grants Under Nasdaq LR 5635(c)(4)
11 Oct 2024 //
GLOBENEWSWIRE
89bio To Participate In HC Wainwright 8th Annual MASH Conference
30 Sep 2024 //
GLOBENEWSWIRE
89bio Announces Inducement Grants Under Nasdaq Listing Rule
19 Sep 2024 //
GLOBENEWSWIRE
89bio Appoints Teresa Perney As Chief Regulatory Officer
16 Sep 2024 //
GLOBENEWSWIRE
89bio to Participate in Upcoming Investor Conferences
29 Aug 2024 //
GLOBENEWSWIRE
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
09 Aug 2024 //
GLOBENEWSWIRE
89bio Appoints Francis Sarena as Chief Operating Officer
07 Aug 2024 //
GLOBENEWSWIRE
89bio Appoints Charles McWherter, Ph.D., to its Board of Directors
05 Aug 2024 //
GLOBENEWSWIRE
89bio Reports Second Quarter 2024 Financial Results and Corporate Updates
05 Aug 2024 //
GLOBENEWSWIRE
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10 Jul 2024 //
GLOBENEWSWIRE
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
14 Jun 2024 //
GLOBENEWSWIRE
89bio To Present ENLIVEN MASH 48-Week Data At EASL
22 May 2024 //
GLOBENEWSWIRE
89bio Initiates Phase 3 Pegozafermin ENLIGHTEN-Cirrhosis Trial In MASH
14 May 2024 //
GLOBENEWSWIRE
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10 May 2024 //
GLOBENEWSWIRE
89bio Reports First Quarter 2024 Financial Results and Provides Corporate Update
09 May 2024 //
GLOBENEWSWIRE
89bio to Participate in the BofA Securities 2024 Health Care Conference
08 May 2024 //
GLOBENEWSWIRE
89bio KOL Webinar On Pegozafermin In Advanced MASH
02 May 2024 //
GLOBENEWSWIRE
89bio Appoints Biotech Industry Veteran, Martin Babler to its Board of Directors
17 Apr 2024 //
GLOBENEWSWIRE
89bio lines up BiBo Pharma to build $135M commercial API plant
11 Apr 2024 //
FIERCE PHARMA
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05 Apr 2024 //
GLOBENEWSWIRE
89bio Receives EMA Status for Pegozafermin in the Treatment of MASH
27 Mar 2024 //
GLOBENEWSWIRE
89bio wins EMA priority status for MASH candidate pegozafermin
27 Mar 2024 //
PHARMACEUTICAL TECHNOLOGY
89bio Initiates Phase 3 ENLIGHTEN-Fibrosis Trial of Pegozafermin
12 Mar 2024 //
GLOBENEWSWIRE
89bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
08 Mar 2024 //
GLOBENEWSWIRE
89bio to Participate in the Leerink Partners Global Biopharma Conference
05 Mar 2024 //
GLOBENEWSWIRE
89bio Reports Fourth Quarter and Full Year 2023 Financial Results
29 Feb 2024 //
GLOBENEWSWIRE
89bio to Participate in the Oppenheimer 34th Annual Life Sciences Conference
06 Feb 2024 //
GLOBENEWSWIRE
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05 Feb 2024 //
GLOBENEWSWIRE
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
19 Dec 2023 //
GLOBENEWSWIRE
89bio Announces Closing of its Upsized Public Offering
12 Dec 2023 //
GLOBENEWSWIRE
89bio Announces Upsized Pricing of $150.0M Public Offering of Common Stock
07 Dec 2023 //
GLOBENEWSWIRE
89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock
06 Dec 2023 //
GLOBENEWSWIRE
89bio Reaches Alignment with the FDA and EMA on Phase 3 Program for Pegozafermin
04 Dec 2023 //
GLOBENEWSWIRE
89bio Announces Data from the ENLIVEN Phase 2b Trial of Pegozafermin
27 Nov 2023 //
GLOBENEWSWIRE
89bio to Participate in the 6th Annual Evercore ISI HEALTHCONx Conference
21 Nov 2023 //
GLOBENEWSWIRE
89bio Announces Additional Data from the ENLIVEN Phase 2b Trial of Pegozafermin
12 Nov 2023 //
GLOBENEWSWIRE
89bio Reports Third Quarter 2023 Financial Results
08 Nov 2023 //
GLOBENEWSWIRE
89bio to Participate in H.C. Wainwright 7áµ—Ê° Annual NASH Investor Conference
17 Oct 2023 //
GLOBENEWSWIRE
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03 Oct 2023 //
GLOBENEWSWIRE
89bio Announces FDA has Granted Breakthrough Designation for Pegozafermin
21 Sep 2023 //
GLOBENEWSWIRE
89bio to Participate in the 2023 Cantor Global Healthcare Conference
20 Sep 2023 //
GLOBENEWSWIRE
89bio to Participate in the H.C. Wainwright 25th Annual Investment Conference
05 Sep 2023 //
GLOBENEWSWIRE
89bio Reports Second Quarter 2023 Financial Results & Provides Corporate Update
09 Aug 2023 //
GLOBENEWSWIRE
89bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
12 Jul 2023 //
GLOBENEWSWIRE
Data from 89bio ENLIVEN Ph2b Trial of Pegozafermin (NASH) Published in The NEJM
24 Jun 2023 //
GLOBENEWSWIRE
Ex-Novartis drug clears NASH test, fueling pursuit of Akero
21 Jun 2023 //
FIERCE BIOTECH
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07 Jun 2023 //
GLOBENEWSWIRE
89bio Announces Late-Breaker Presentation of Data from the Phase 2 ENLIVEN Study
07 Jun 2023 //
GLOBENEWSWIRE
89bio Initiates Phase 3 ENTRUST Trial of Pegozafermin
23 May 2023 //
GLOBENEWSWIRE
89bio Reports First Quarter 2023 Financial Results and Provides Corporate Update
04 May 2023 //
GLOBENEWSWIRE
89bio to Participate in Upcoming Investor Conferences
02 May 2023 //
GLOBENEWSWIRE
